Clinical trials
Phase 3 Psychotic Disorders trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
58 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 3 |
| 2003 | 2 |
| 2004 | 6 |
| 2005 | 7 |
| 2006 | 8 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 3 |
| 2013 | 3 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 46 |
| Recruiting | 6 |
| Terminated | 5 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 |
| Corcept Therapeutics | 4 |
| Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 3 |
| Sumitomo Pharma America, Inc. | 3 |
| ACADIA Pharmaceuticals Inc. | 2 |
| Alkermes, Inc. | 2 |
| BioXcel Therapeutics Inc | 2 |
| Eli Lilly and Company | 2 |
| Janssen Scientific Affairs, LLC | 2 |
| Northwestern University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Psychotic Disorders | 58 |
| Schizophrenia | 36 |
| Mental Disorders | 9 |
| Bipolar Disorder | 8 |
| Major Depressive Disorder | 7 |
| Alzheimer Disease | 4 |
| Psychomotor Agitation | 3 |
| Anxiety Disorders | 2 |
| Dementia | 2 |
| Lethargy | 2 |
Trials
Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.